• Glofitamab, sold under the brand name Columvi, is a bispecific monoclonal antibody used for the treatment of large B-cell lymphoma. It is a bispecific...
    15 KB (1,043 words) - 23:43, 23 March 2024
  • Thumbnail for Bi-specific T-cell engager
    Bi-specific T-cell engagers (BiTEs) are a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They...
    9 KB (1,455 words) - 03:04, 18 May 2024
  • (Bevacizumab) Leukemia/lymphoma lymphoid: CD3 (Glofitamab, Elranatamab, Mosunetuzumab), CD20 (Glofitamab Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab...
    12 KB (741 words) - 18:39, 6 May 2024
  • (Bevacizumab) Leukemia/lymphoma lymphoid: CD3 (Glofitamab, Elranatamab, Mosunetuzumab), CD20 (Glofitamab Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab...
    12 KB (758 words) - 23:46, 14 March 2024
  • Thumbnail for Diffuse large B-cell lymphoma
    adult patients with relapsed or refractory DLBCL after systemic therapy. Glofitamab (Columvi) is a bispecific monoclonal antibody that was approved for medical...
    69 KB (8,143 words) - 18:36, 22 January 2024
  • Thumbnail for List of therapeutic monoclonal antibodies
    carcinoma Glembatumumab vedotin mab human GPNMB melanoma, breast cancer Glofitamab Columvi BsAb humanized CD20, CD3 Y diffuse large B-cell lymphoma Golimumab...
    134 KB (4,024 words) - 02:01, 18 May 2024
  • Mosunetuzumab L01FX26 Mirvetuximab soravtansine L01FX27 Epcoritamab L01FX28 Glofitamab L01FX29 Talquetamab L01FY01 Pertuzumab and trastuzumab L01FY02 Nivolumab...
    12 KB (877 words) - 15:36, 25 January 2024
  • amivantamab, tebentafusp, faricimab, teclistamab, mosunetuzumab, epcoritamab, glofitamab. Among the bsAb programs currently under development, the combination...
    29 KB (3,308 words) - 18:16, 18 March 2024
  • (INN) glisoxepide (INN) globin zinc insulin injection (INN) Glofil-125 glofitamab (INN) gloxazone (INN) gloximonam (INN) Glucagen glucagon (INN) glucalox...
    14 KB (643 words) - 05:50, 26 April 2024
  • Etaracizumab§ Farletuzumab§ Ficlatuzumab§ Flotetuzumab§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab§ Inotuzumab ozogamicin Labetuzumab§ Lifastuzumab vedotin§...
    3 KB (129 words) - 01:04, 19 July 2023